info:eu-repo/semantics/article
Genetics of combined pituitary hormone deficiency: Roadmap into the genome era
Fecha
2016-12Registro en:
Fang, Qing; George, Akima S.; Brinkmeier, Michelle L.; Mortensen, Amanda H.; Gergics, Peter; et al.; Genetics of combined pituitary hormone deficiency: Roadmap into the genome era; Endocrine Society; Endocrine Reviews; 37; 6; 12-2016; 636-675
0163-769X
1945-7189
CONICET Digital
CONICET
Autor
Fang, Qing
George, Akima S.
Brinkmeier, Michelle L.
Mortensen, Amanda H.
Gergics, Peter
Cheung, Leonard Y.M.
Daly, Alexandre Z.
Ajmal, Adnan
Pérez Millán, María Inés
Bilge Ozel, A.
Kitzman, Jacob
Mills, Ryan E.
Li, Jun Z.
Camper, Sally
Resumen
The genetic basis for combined pituitary hormone deficiency (CPHD) is complex, involving 30 genes in a variety of syndromic and nonsyndromic presentations. Molecular diagnosis of this disorder is valuable for predicting disease progression, avoiding unnecessary surgery, and family planning. Weexpect that the application of high throughput sequencing will uncover additional contributing genes and eventually become a valuable tool for molecular diagnosis. For example, in the last 3 years, six new genes have been implicated in CPHD using whole-exome sequencing. In this review, we present a historical perspective on gene discovery for CPHD and predict approaches that may facilitate future gene identification projects conducted by clinicians and basic scientists. Guidelines for systematic reporting of genetic variants and assigning causality are emerging. We apply these guidelines retrospectively to reports of the genetic basis of CPHD and summarize modes of inheritance and penetrance for each of the known genes. In recent years, there have been great improvements in databases of genetic information for diverse populations. Some issues remain that make molecular diagnosis challenging in some cases. These include the inherent genetic complexity of this disorder, technical challenges like uneven coverage, differing results from variant calling and interpretation pipelines, the number of tolerated genetic alterations, and imperfect methods for predicting pathogenicity.Wediscuss approaches for future research in the genetics of CPHD.